Laboratory Corporation of America Holdings with ticker code (LH) have now 13 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between 285 and 210 and has a mean target at $248.54. Given that the stocks previous close was at $201.17 and the analysts are correct then we can expect a percentage increase in value of 23.5%. The 50 day MA is $212.06 while the 200 day moving average is $203.18. The market capitalization for the company is 18.13B. The stock price is currently at: 204.67 USD
The potential market cap would be $22,403,764,077 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 19.24, revenue per share of 167.11 and a 5.51% return on assets.
Laboratory Corporation of America Holdings is a global life sciences company. The Company provides information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make decisions. The Company’s segments include Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). The Dx segment is an independent clinical laboratory business. It offers a menu of frequently requested and specialty diagnostic tests through an integrated network of primary and specialty laboratories across the United States. In addition to diagnostic testing along with occupational and wellness testing for employers and forensic DNA analysis, Dx segment also offers a range of other testing services. The DD segment is a contract research organizations business that provides end-to-end drug development services. The DD segment provides these services predominantly to pharmaceutical, biotechnology and medical device companies across the world. It serves clients in more than 100 countries.
